Clinical intervention of idecalcitol combined with whey protein powder and exercise for sarcopenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400085142

Enrollment

Unknown

Registered

2024-05-31

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

Control group:After enrollment, professional doctors will conduct a comprehensive assessment of their basic conditions and provide routine interventions, mainly including basic nutrition intervention

experimental group 1:On the basis of the control group, whey protein powder was given to supplement for 12 weeks.60 grams of protein per day is taken in three divided doses for 12 consecutive weeks. A

experimental group 2:On the basis of the control group, whey protein powder and eldecalcitol were given for supplementation for 12 weeks. (Supplementing whey protein powder: The protein intake is 60 g

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age 30 or above; ? Meeting the diagnostic criteria for sarcopenia according to the definition of AWGS; ? Able to walk, willing to accept a comprehensive intervention plan, and guarantee to complete the treatment course; ? Both patients and their families agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Resting systolic blood pressure > 200 mmHg or resting diastolic blood pressure > 100 mmHg; ? Severe heart disease: moderate to severe aortic valve stenosis, acute pericarditis, acute myocarditis, myocardial infarction, uncontrollable arrhythmia; ? Acute stroke within the past 2 years; ? Severe airway obstruction; ? Lower limb fractures in the past 1 year or upper limb fractures in the past 6 months; ? Hypercalcemia (corrected albumin serum calcium > 2.60 mmol/L); ? Active malignant tumors; ? Chronic kidney disease stages 4-5; ? Mental illness or moderate to severe cognitive impairment; ? Long-term immobilization; ? Other diseases that may interfere with the evaluation of muscle mass, muscle strength, and physical function; ? Unable to cooperate with treatment due to other reasons; ? Life expectancy less than 6 months.

Design outcomes

Primary

Measure	Time frame
muscle mass;Grip strength,;	—

Secondary

Measure	Time frame
6-meter walking speed,;incidence of adverse reactions;	—

Countries

China

Contacts

Public ContactTu Jianfeng

Zhejiang Provincial People's Hospital

Tutu5800@163.com+86 159 2566 9920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026